A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
NCT03093116
This study is recruiting at 10 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Locally Advanced Solid Tumors
- Metastatic Solid Tumors
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 12 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Turning Point Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- May 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- St Joseph Heritage Healthcare · Santa Rosa, CA
Florida · 1
- Memorial Healthcare System · Hollywood, FL
Georgia · 1
- University Cancer and Blood Center · Athens, GA
Illinois · 1
- University of Chicago · Chicago, IL
Massachusetts · 1
- Massachusetts General Hospital, · Boston, MA
Missouri · 1
- Washington University Infusion Center Pharmacy · St Louis, MO
Ohio · 1
- The Ohio State University Wexner Medical Center · Columbus, OH
Tennessee · 1
- Baptist Memorial Hospital Baptist Cancer Center · Memphis, TN
Texas · 2
- UT Southwestern Medical Center · Dallas, TX
- MD Anderson Cancer Center · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.